COVID Will Transform Cancer Care for Patients and Providers

With the novel coronavirus putting immunocompromised people in particular at risk and hospitals focusing on treating people with COVID-19, many people with cancer are experiencing disruptions in their treatment. And as studies show people forgoing diagnostic tests such as mammograms and colonoscopies, industry experts worry that as we emerge on the other side of the pandemic, there will be an uptick in these procedures — as well as an increase in people receiving a cancer diagnosis that’s at an advanced stage.

“COVID-19 has had a major impact upon all aspects of the health care industry,” says Winston Wong, Pharm.D., president of W-Squared Group. “Cancer care is no exception.”

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
September 12

New FDA Approvals: FDA Approved Citius’ Lymphir for CTCL

READ MORE
September 12

Evernorth Reveals Stelara Biosimilar Strategy, but Will Others Get Same Discount?

READ MORE
September 12

Quantile Health Wants to Help Self-Insured Plans Access CGTs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today